Orchid Pharma Limited (ORCHPHARMA) Financial Results — Revenue ₹811 Cr

Revenue: ₹811 Cr

📢 Key Event
Orchid Pharma reported Q4 FY26 revenue of ₹238 crores and FY26 revenue of ₹811 crores, with EBITDA of ₹42.3 crores in Q4 and ₹101 crores for the full year.

🔄 What Changed
Revenue declined 12% YoY to ₹811 crores and EBITDA dropped 35% YoY to ₹101 crores; gross margins recovering to 31-32% by Q4 after Q1 inventory losses from 15-20% price drops; 7ACA project commissioning shifted to Q1 2027; Cefiderocol launch window updated to Q2-Q3 2027; capex of INR50 crores announced for fill-finish facilities.

🔮 What's Next
Cefiderocol launch planned for Q2-Q3 2027; 5 planned U.S. product launches; 10-15% growth target for FY27; 12% EBITDA margin guidance maintained for base business; INR50 crores capex for fill-finish facilities; 7ACA pricing remains stable at $61 (range: $55-$65); lifetime sales projection of $1-2 billion for Enmetazobactam; Shionogi plant commissioning in December 2026 enabling H2 2027 Indian launch.

💡 Investor Takeaway
Orchid Pharma is rebuilding with disciplined execution, targeting long-term growth through U.S. market expansion and strategic projects like Cefiderocol and 7ACA, while managing near-term margin pressures from pricing and inventory adjustments.

Orchid Pharma reported Q4 FY26 revenue of ₹238 crores and FY26 revenue of ₹811 crores, with EBITDA of ₹42.3 crores in Q4 and ₹101 crores for the full year. YoY revenue declined 12% to ₹811 crores from ₹922 crores, while EBITDA dropped 35% to ₹101 crores from ₹155 crores. The company highlighted strategic progress including the Dhanuka Laboratories merger, 7ACA project commissioning in Q1 2027, and Cefiderocol launch planning for Q2-Q3 2027. Management emphasized U.S. market expansion targeting a 1.2 billion segment with pent-up demand, supported by FDA-approved facilities and five planned product launches. Gross margins are recovering to 31-32% by Q4 after Q1 inventory losses from 15-20% price drops. Capex of INR50 crores is allocated for fill-finish facilities tied to Cefiderocol, with 7ACA pricing stable at $61 (range: $55-$65).

📄 View Original Announcement (PDF)

📊 Stock Analysis — ORCHPHARMA ✨ Ask AI About This